Curatis Holding Reports Strong H1 2024 Growth and Advances Rare Disease Drug Pipeline
Curatis Holding has reported its financial results for the first half of 2024, showcasing significant growth in its core distribution business despite only including two months of data from its recently acquired subsidiary, Curatis AG. The company’s revenues reached CHF 2.0 million, with Curatis AG contributing to this

